
Eli Lilly Leads GLP-1 Market on Growth as Novo Nordisk Presents Value Case, Analysis Shows
An analysis of the GLP-1 drug market highlights Eli Lilly's dominance in growth and pipeline strength, while Novo Nordisk's lower valuation offers a potential value play. Amgen is positioned as a speculative contender with its drug candidate in late-stage trials.







